JP6373867B2 - Ｌｆａ−１阻害剤製剤 - Google Patents

Ｌｆａ−１阻害剤製剤 Download PDF

Info

Publication number
JP6373867B2
JP6373867B2 JP2015549612A JP2015549612A JP6373867B2 JP 6373867 B2 JP6373867 B2 JP 6373867B2 JP 2015549612 A JP2015549612 A JP 2015549612A JP 2015549612 A JP2015549612 A JP 2015549612A JP 6373867 B2 JP6373867 B2 JP 6373867B2
Authority
JP
Japan
Prior art keywords
formula
compound
composition
certain embodiments
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015549612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503058A5 (enExample
JP2016503058A (ja
Inventor
メアリー・ニューマン
ウィリアム・フンケ
Original Assignee
サルコード・バイオサイエンス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6373867(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サルコード・バイオサイエンス・インコーポレイテッド filed Critical サルコード・バイオサイエンス・インコーポレイテッド
Publication of JP2016503058A publication Critical patent/JP2016503058A/ja
Publication of JP2016503058A5 publication Critical patent/JP2016503058A5/ja
Application granted granted Critical
Publication of JP6373867B2 publication Critical patent/JP6373867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015549612A 2012-12-19 2013-12-18 Ｌｆａ−１阻害剤製剤 Active JP6373867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US61/739,609 2012-12-19
US201361758147P 2013-01-29 2013-01-29
US61/758,147 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (3)

Publication Number Publication Date
JP2016503058A JP2016503058A (ja) 2016-02-01
JP2016503058A5 JP2016503058A5 (enExample) 2016-07-28
JP6373867B2 true JP6373867B2 (ja) 2018-08-15

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015549612A Active JP6373867B2 (ja) 2012-12-19 2013-12-18 Ｌｆａ−１阻害剤製剤

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP2934510B1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA028008B1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX391620B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
EP3955926A4 (en) * 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
KR20230110516A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 눈 장애의 치료를 위한 화합물 및 방법
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
JP3631490B2 (ja) * 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
JP5794721B2 (ja) * 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
EP1901708B1 (en) * 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
EP2441453B1 (en) * 2009-06-10 2014-11-26 Mitotech SA Pharmaceutical composition for use in medical and veterinary ophthalmology
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
BR112012012387A2 (pt) * 2009-11-23 2019-09-24 Allergan Inc 7-[3,5-di-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) na forma cristalina ii, métodos para a preparação e métodos de utilização da mesma
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
US20130005708A1 (en) * 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
ES2978927T3 (es) * 2012-03-29 2024-09-23 Epion Therapeutics Inc Soluciones de tratamiento ocular, dispositivos de administración y métodos de aumento de la administración
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
BR112015014367B1 (pt) 2022-11-22
KR20150100763A (ko) 2015-09-02
ES2846724T3 (es) 2021-07-29
MX2019012375A (es) 2020-01-20
ZA201608069B (en) 2017-11-29
US20220000859A1 (en) 2022-01-06
EA028008B1 (ru) 2017-09-29
CN104955453A (zh) 2015-09-30
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
EP3827823A1 (en) 2021-06-02
IL239490A0 (en) 2015-08-31
KR101891144B1 (ko) 2018-08-23
US11058677B2 (en) 2021-07-13
EA201591180A1 (ru) 2015-12-30
US20150320737A1 (en) 2015-11-12
HUE052299T2 (hu) 2021-04-28
CA2894170A1 (en) 2014-06-26
BR112015014367A2 (pt) 2017-07-11
AU2013361579A1 (en) 2015-06-18
AU2013361579B2 (en) 2018-05-24
EP2934510A1 (en) 2015-10-28
ZA201504404B (en) 2020-01-29
NZ708821A (en) 2020-03-27
PL2934510T3 (pl) 2021-07-05
IL239490B (en) 2018-12-31
MX2015007540A (es) 2016-04-13
EA201791321A1 (ru) 2018-04-30
MX368876B (es) 2019-10-21
CA2894170C (en) 2021-08-10
SI2934510T1 (sl) 2021-02-26
JP2016503058A (ja) 2016-02-01
DK2934510T3 (da) 2021-01-25
MX391620B (es) 2025-03-19
HK1214536A1 (zh) 2016-07-29
EP2934510B1 (en) 2020-10-28
PT2934510T (pt) 2021-01-13
CN104955453B (zh) 2018-09-18
WO2014100135A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
JP6373867B2 (ja) Ｌｆａ−１阻害剤製剤
JP2023041804A (ja) 安定で保存剤非含有の散瞳および抗炎症注射用液剤
US20120093876A1 (en) Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
US20120095097A1 (en) Ophthalmic composition
JP5275214B2 (ja) 酸化に不安定な成分を含む眼科用安定組成物
CN112933075A (zh) 局部给药的葛根相关药物组合物
JP2012520882A5 (enExample)
EP4248970A1 (en) Opthalmic compositions comprising cetirizine and tocofersolan
JP2002114686A (ja) 点眼剤組成物
EP3860581A1 (en) Cysteamine zinc complex and method of using a cysteamine zinc complex
US20220071924A1 (en) Treatment of ocular diseases with ophthalmic tapinarof compositions
JP5013735B2 (ja) 眼粘膜適用製剤
CA3169401A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
HK1214536B (zh) Lfa-1抑制剂制剂
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
HK1214963B (en) Lfa-1 inhibitor formulations
RU2488402C1 (ru) Средство, обладающее противовоспалительным и противоаллергическим действием
RU2238092C2 (ru) Водная лекарственная композиция для лечения заболеваний кожи
KR20250133899A (ko) 국소 약학적 조성물 및 이의 용도
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
BR112020018377A2 (pt) Métodos de uso e composições farmacêuticas de um inibidor de syk seletivo
WO1995033456A2 (en) Reducing intraocular pressure using aryloxy- and aryl-acetic acids
JP2004075578A (ja) 眼科疾患予防および治療用薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180625

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180718

R150 Certificate of patent or registration of utility model

Ref document number: 6373867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250